title: Adolescent hodgkin lymphoma: are treatment results more favorable with pediatric than with adult regimens?
abstract: BACKGROUND
  The aim of our work was to compare the treatment modalities and the survival rates in adolescents (14 to 21 y) with Hodgkin lymphoma (HL) treated with adult (A) or with pediatric (P) regimens.
  
  
  METHODS
  From January 1990 to December 2004, 134 (A) and 111 (P) adolescents with HL were treated. Male:female ratio was 1:1.48 (A) and 1:1.36 (P), the mean-age 18.6 (A) and 15.8 years (P), respectively.
  
  
  RESULTS
  The patients were treated either with doxorubicin, bleomycin, vinblastine and dacarbazine (A) or with OPPA/OEPA ± COPP regimens (P). About 82% (A) and 89% (P) of the patients received radiotherapy. Relapse rates were 13% (A) and 14% (P). Fourteen patients died in group (A) and 9 in group (P). There were no significant differences in the overall survival and event-free survival rates at 5 and 10 years between the 2 patient's groups. For children under age of 18 years old overall survival was 92.8 ± 3% at 5 and 89.6 ± 3% at 10 years in group (P) and 89.4 ± 4% at 5 years and 83.1 ± 6% at 10 years (P=0.2822) in group (A). For children under the age of 18 years event-free survival was 82.4 ± 4% at 5 and 10 years in group (P) and 69.6 ± 7% at 5 years and 59.1 ± 8% at 10 years (P=0.0192) in group (A).
  
  
  CONCLUSIONS
  In case of the patients younger than 18 years, the survival rates are more favorable by using pediatric regimens, so these patients might have a benefit if they are treated in pediatric institutes.
authors.affiliation: 2nd Department of Pediatrics, Semmelweis University ‡National Institute for Oncology, Budapest, Hungary. muller@gyer2.sote.hu
authors.forename: Judit
authors.initials: J
authors.lastname: Müller
authors.forename: Arpád
authors.initials: A
authors.lastname: Illés
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Molnár
authors.forename: András
authors.initials: A
authors.lastname: Rosta
authors.forename: László
authors.initials: L
authors.lastname: Váróczy
authors.forename: Gábor
authors.initials: G
authors.lastname: Kovács
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide; D003606:Dacarbazine / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D011241:Prednisone; D011344:Procarbazine; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone